Stock FDMT 4D MOLECULAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
24 USD -2.60% Intraday chart for 4D Molecular Therapeutics, Inc. -4.57% +18.46%
May. 15 Transcript : 4D Molecular Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
May. 09 4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
GL
Transcript : 4D Molecular Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
GL
4DMT to Participate in Upcoming Investor Conference
GL
4DMT to Participate in Upcoming Investor Conference
AQ
4DMT Announces Presentations at ARVO 2024 Annual Meeting
GL
Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target
MT
RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier
MT
Certain Restricted Stock Units of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
Certain Stock Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
Certain Warrants of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing
MT
BMO Capital Cuts 4D Molecular Therapeutics' Price Target to $63 From $70, Keeps Outperform Rating
MT
Jefferies Raises 4D Molecular Therapeutics' Price Target to $58 From $30, Maintains Buy Rating
MT
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis
MT
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
GL
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
CI
Transcript : 4D Molecular Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FDMT Stock
  4. News 4D Molecular Therapeutics, Inc.